BOC International: Health Insurance Commercial Insurance Catalogue Launches Multiple Payment Systems Innovative Drug Growth Space

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that BOC International released a research report stating that it gave the mainland pharmaceutical industry a leading rating. The National Health Insurance Administration held the “2025 Innovative Drug High Quality Development Conference” to officially announce the results of this round of health insurance negotiations and negotiations on the commercial insurance innovative drug catalogue. Most of the innovative pharmaceutical companies covered by the bank have received new medical insurance coverage or successful contract renewals. Among them, Hengrui Pharmaceutical (01276), Cinda Biotech (01801), Kangfang Biotech (09926), and China Biopharmaceuticals (01177) have received new coverage or new indications.

The bank believes that more new drugs entering the catalogue will help improve the level of clinical drug use and the overall return on research and development in the innovative drug industry. At the same time, the introduction of commercial insurance funds will bring important incremental capital to innovative drug payments. In the future, commercial health insurance is expected to be misaligned with basic medical insurance, laying the foundation for the establishment of a diversified payment system. The bank is optimistic about the sales growth potential of newly incorporated varieties/indications in 2026, especially the incremental release space for potentially large single products such as Kangfang Biotech. Regarding commercial insurance, the bank also focused on the actual execution and payment of the first batch of catalogues, dynamic adjustments of lists and pricing, and long-term development opportunities brought about by real-world data accumulation.